Filing Details

Accession Number:
0001415889-23-017025
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-29 18:00:07
Reporting Period:
2023-12-27
Accepted Time:
2023-12-29 18:00:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1798749 Aerovate Therapeutics Inc. AVTE Pharmaceutical Preparations (2834) 831377888
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1868997 Hunter Gillies C/O Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham MA 02451
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-27 125 $2.14 3,376 No 4 M Direct
Common Stock Disposition 2023-12-27 125 $24.50 3,251 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-12-27 25 $0.00 25 $2.14
Common Stock Stock Option (Right to Buy) Disposition 2023-12-27 100 $0.00 100 $2.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
16,269 2031-04-01 No 4 M Direct
109,540 2031-04-01 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
  2. A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.
  3. A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.